On April 29, 2021 Seagen Inc. (Nasdaq:SGEN) reported the presentation of new data from its growing pipeline of marketed and investigational therapies at the virtual scientific program of the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held June 4-8 (Press release, Seagen, APR 29, 2021, View Source [SID1234578807]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Emerging data and the breadth of our clinical development programs continue to illustrate progress across our oncology portfolio, highlighting the company’s research efforts in multiple cancers with a high unmet need," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "Notably, we are looking forward to sharing updated results of the EV-103 and EV-201 clinical trials for PADCEV (enfortumab vedotin-ejfv) in locally advanced or metastatic urothelial cancer and additional data from the HER2CLIMB trial of TUKYSA (tucatinib) in previously treated HER2+ metastatic breast cancer patients."
Key data to be presented include:
Abstract Title
Abstract #
Presentation type
Lead Author
PADCEV (enfortumab vedotin-ejfv)
Study EV-103: Update on durability results and long-term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)
4528
Poster Presentation
T. Friedlander
Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2
4524
Poster Presentation
B. McGregor
Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized Phase 3 trial of enfortumab vedotin vs chemotherapy
4539
Poster Presentation
R. Mamtani
KEYNOTE-B15/EV-304: Randomized Phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)
TPS4587
Poster Presentation
C. Hoimes
TUKYSA (tucatinib)
Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)
1043
Poster Presentation
G. Curigliano
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer
1044
Poster Presentation
E. Stringer-Reasor
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress)
TPS3151
Poster Presentation
T. Stinchcombe
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)
TPS1097
Poster Presentation
I. Krop
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
TPS595
Poster Presentation
C. O’Sullivan
ADCETRIS (brentuximab vedotin)
Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the Phase 3 Echelon-1 study
7528
Poster Presentation
H. Crosswell
Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (trial in progress)
TPS7571
Poster Presentation
N. Bartlett
Tisotumab vedotin
Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-Line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress)
TPS5596
Poster Presentation
I. Vergote
Early Pipeline
SGNTGT-001: A Phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress)
TPS2657
Poster Presentation
E. Garralda
A Phase 1 study of SGN-B6A, an antibody-drug conjugate targeting Integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, trial in progress)
TPS3144
Poster Presentation
A. Patnaik